Adjuvant Treatment in Cancer Patients with Neoantigen-primed DC Vaccine : a Single-arm, Open-label, Prospective Clinical Trial
Who is this study for? Patients with Gastric Cancer, Hepatocellular Carcinoma, Non-Small-Cell Lung Cancer, Colon Rectal Cancer
What treatments are being studied? DC Vaccine Subcutaneous Administration
Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
The study is aimed to the test efficacy and safety of neoantigen-primed dendritic cell (DC) cell vaccine therapy for postoperative locally advanced gastric cancer, hepatocellular carcinoma, lung cancer and colorectal cancer, and to explore the biomarkers related to efficacy and adverse event.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 100
Healthy Volunteers: f
View:
• Participants with a first diagnosis of gastric cancer, hepatocellular carcinoma, non-small cell lung cancer, colorectal cancer who have undergone a curative resection or ablation
• Anticipated life time \> 3month
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
• Adequate organ functions
Locations
Other Locations
China
Qiu Li
RECRUITING
Chengdu
Contact Information
Primary
Qiu Li
liqiu@scu.edu.cn
+86 028-85422589
Time Frame
Start Date: 2019-06-01
Estimated Completion Date: 2026-06-01
Participants
Target number of participants: 80
Treatments
Experimental: cell_therapy
tumor neoantigen primed DC vaccines are administrated, 2-3 week interval, totally 3-5 times
Related Therapeutic Areas
Sponsors
Leads: Sichuan University